Mounjaro (Tirzepatide)

Description

Mounjaro® (Tirzepatide) is a once-weekly injectable prescription medication developed by Eli Lilly and Company for the management of Type 2 Diabetes Mellitus. It is the first medication in its class to activate both GLP-1 and GIP receptors, helping improve blood sugar control through multiple metabolic pathways.

Tirzepatide works by enhancing insulin secretion, reducing glucagon levels, and slowing gastric emptying, which together contribute to improved glycemic control. Many patients may also experience weight reduction as part of treatment, when used alongside appropriate diet and lifestyle measures, as directed by a healthcare professional.

Mounjaro is supplied as a pre-filled, single-dose injection pen designed for subcutaneous administration once weekly. The pen is user-friendly and intended for self-administration after proper medical instruction.

This medication is available in multiple dosage strengths, allowing healthcare providers to individualize treatment based on patient needs and tolerability.

⚠️ Prescription only. Use strictly under medical supervision.

Key Features

• Dual-action GLP-1 & GIP receptor agonist

• Once-weekly subcutaneous injection

• Pre-filled, ready-to-use pen

• Clinically proven to improve glycemic control

• Manufactured by Eli Lilly and Company

Indication

• Management of Type 2 Diabetes Mellitus

• May support weight reduction as prescribed by a physician

Storage

• Store refrigerated at 2°C–8°C

• Do not freeze

• Protect from light